Elizabeth Anderson
Stock Analyst at Evercore ISI Group
(2.59)
# 2,725
Out of 5,182 analysts
159
Total ratings
57%
Success rate
-1.38%
Average return
Main Sectors:
Stocks Rated by Elizabeth Anderson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ELV Elevance Health | Maintains: In-Line | $345 → $360 | $344.31 | +4.56% | 2 | Apr 23, 2026 | |
| TDOC Teladoc Health | Maintains: In-Line | $5 → $6 | $5.63 | +6.57% | 8 | Apr 8, 2026 | |
| PRVA Privia Health Group | Maintains: Outperform | $30 → $26 | $23.39 | +11.16% | 6 | Apr 8, 2026 | |
| OMDA Omada Health | Maintains: Outperform | $20 → $15 | $14.13 | +6.16% | 2 | Apr 8, 2026 | |
| NVST Envista Holdings | Maintains: Outperform | $32 → $30 | $26.50 | +13.21% | 5 | Apr 8, 2026 | |
| LH Labcorp Holdings | Maintains: Outperform | $280 → $300 | $264.74 | +13.32% | 8 | Apr 8, 2026 | |
| IQV IQVIA Holdings | Maintains: Outperform | $225 → $185 | $163.35 | +13.25% | 8 | Apr 8, 2026 | |
| HSIC Henry Schein | Maintains: Outperform | $100 → $90 | $76.86 | +17.10% | 4 | Apr 8, 2026 | |
| HNGE Hinge Health | Maintains: Outperform | $50 → $45 | $43.76 | +2.83% | 4 | Apr 8, 2026 | |
| FTRE Fortrea Holdings | Maintains: Outperform | $25 → $14 | $9.49 | +47.52% | 12 | Apr 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $260 → $240 | $200.00 | +20.00% | 11 | Apr 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $1,000 → $950 | $823.22 | +15.40% | 8 | Apr 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $220 → $210 | $199.27 | +5.38% | 6 | Apr 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $30 → $25 | $23.42 | +6.75% | 11 | Apr 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $12 → $15 | $11.77 | +27.44% | 9 | Feb 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $55 | $44.57 | +23.40% | 2 | Feb 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $27 | $25.19 | +7.19% | 5 | Feb 18, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $180 → $200 | $188.08 | +6.34% | 16 | Feb 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $85 → $95 | $77.58 | +22.45% | 10 | Oct 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $4 → $3 | $1.37 | +118.98% | 9 | Oct 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $125 → $75 | $25.00 | +200.00% | 5 | Jul 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $68 → $26 | $1.22 | +2,051.64% | 3 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $35 → $15 | $1.77 | +747.46% | 3 | Mar 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $11 | $0.89 | +1,135.96% | 2 | Jan 4, 2022 |
Elevance Health
Apr 23, 2026
Maintains: In-Line
Price Target: $345 → $360
Current: $344.31
Upside: +4.56%
Teladoc Health
Apr 8, 2026
Maintains: In-Line
Price Target: $5 → $6
Current: $5.63
Upside: +6.57%
Privia Health Group
Apr 8, 2026
Maintains: Outperform
Price Target: $30 → $26
Current: $23.39
Upside: +11.16%
Omada Health
Apr 8, 2026
Maintains: Outperform
Price Target: $20 → $15
Current: $14.13
Upside: +6.16%
Envista Holdings
Apr 8, 2026
Maintains: Outperform
Price Target: $32 → $30
Current: $26.50
Upside: +13.21%
Labcorp Holdings
Apr 8, 2026
Maintains: Outperform
Price Target: $280 → $300
Current: $264.74
Upside: +13.32%
IQVIA Holdings
Apr 8, 2026
Maintains: Outperform
Price Target: $225 → $185
Current: $163.35
Upside: +13.25%
Henry Schein
Apr 8, 2026
Maintains: Outperform
Price Target: $100 → $90
Current: $76.86
Upside: +17.10%
Hinge Health
Apr 8, 2026
Maintains: Outperform
Price Target: $50 → $45
Current: $43.76
Upside: +2.83%
Fortrea Holdings
Apr 8, 2026
Maintains: Outperform
Price Target: $25 → $14
Current: $9.49
Upside: +47.52%
Apr 8, 2026
Maintains: Outperform
Price Target: $260 → $240
Current: $200.00
Upside: +20.00%
Apr 8, 2026
Maintains: Outperform
Price Target: $1,000 → $950
Current: $823.22
Upside: +15.40%
Apr 8, 2026
Maintains: In-Line
Price Target: $220 → $210
Current: $199.27
Upside: +5.38%
Apr 8, 2026
Downgrades: In-Line
Price Target: $30 → $25
Current: $23.42
Upside: +6.75%
Feb 27, 2026
Maintains: In-Line
Price Target: $12 → $15
Current: $11.77
Upside: +27.44%
Feb 26, 2026
Maintains: Outperform
Price Target: $50 → $55
Current: $44.57
Upside: +23.40%
Feb 18, 2026
Maintains: Outperform
Price Target: $40 → $27
Current: $25.19
Upside: +7.19%
Feb 5, 2026
Maintains: Outperform
Price Target: $180 → $200
Current: $188.08
Upside: +6.34%
Oct 30, 2025
Maintains: Outperform
Price Target: $85 → $95
Current: $77.58
Upside: +22.45%
Oct 8, 2025
Maintains: In-Line
Price Target: $4 → $3
Current: $1.37
Upside: +118.98%
Jul 9, 2025
Maintains: In-Line
Price Target: $125 → $75
Current: $25.00
Upside: +200.00%
Mar 16, 2022
Maintains: In-Line
Price Target: $68 → $26
Current: $1.22
Upside: +2,051.64%
Mar 2, 2022
Downgrades: In-Line
Price Target: $35 → $15
Current: $1.77
Upside: +747.46%
Jan 4, 2022
Downgrades: In-Line
Price Target: $11
Current: $0.89
Upside: +1,135.96%